STEK Stemtech Corp
Wholesale-Drugs, Proprietaries & Druggists' Sundries · OTC · SEC CIK 1511820 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.9%
TTM net income YoY-18.7%
TTM EPS YoY100.0%
Revenue 3-yr CAGR-26.6%
Net income 3-yr CAGR—
Margins
Gross margin75.7%
Operating margin-134.0%
Net margin-191.3%
FCF margin-35.5%
EBITDA margin-124.8%
Returns
ROE—
ROA-102.2%
ROIC (approx.)—
Asset turnover0.53x
Leverage & solvency
Liabilities / assets361.0%
Debt / equity—
Current ratio0.05x
Interest coverage-2.62x
Cash quality & payout
Operating cash flow / net income0.19x
Accruals ratio-83.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $282,484 | $629,312 | $462,957 | $458,109 | $852,300 | $697,925 | $868,046 | $1.31M |
| Cost of revenue | $68,914 | $163,639 | $109,304 | $103,432 | $169,817 | $145,909 | $147,782 | $268,593 |
| Gross profit | $213,570 | $465,673 | $353,653 | $354,677 | $682,483 | $552,016 | $720,264 | $1.05M |
| R&D expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A expense | $539,193 | $539,719 | $1.40M | $1.25M | $882,435 | $697,987 | $1.73M | $1.09M |
| Operating income | -$371,398 | -$125,567 | -$1.09M | -$863,937 | -$339,217 | -$300,988 | -$1.20M | $33,163 |
| Interest expense | $109,526 | $112,734 | $97,659 | $618,356 | $508,699 | $79,727 | $245,368 | $537,503 |
| Pretax income | -$478,575 | -$292,358 | -$1.25M | -$1.48M | -$812,541 | -$296,280 | -$1.46M | -$396,580 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$478,575 | -$292,358 | -$1.25M | -$1.48M | -$809,406 | -$293,145 | -$1.46M | -$396,580 |
| EBITDA | -$329,525 | -$83,694 | -$1.05M | -$822,072 | -$297,340 | -$259,111 | -$1.16M | $218,160 |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | -0.01 | 0.00 | -0.01 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | -0.01 | 0.00 | -0.01 | — |
| Weighted avg. shares (diluted) | 2.96B | 2.08B | 812.14M | — | 150.10M | 142.44M | 118.70M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $255,555 | $246,772 | $256,149 | $238,245 | $255,416 | $272,450 | $305,836 | $255,298 |
| Inventory | $296,320 | $311,277 | $325,700 | $217,338 | $234,614 | $274,807 | $188,400 | $197,355 |
| Current assets | $558,275 | $571,233 | $602,589 | $457,062 | $1.02M | $1.10M | $936,079 | $921,746 |
| PP&E, net | $0 | — | $0 | $0 | — | — | — | $0 |
| Goodwill | $467,409 | $467,409 | $467,409 | $467,409 | $467,409 | $467,409 | $467,409 | $467,409 |
| Intangibles | $2.08M | $2.12M | $2.17M | $2.21M | $2.25M | $2.29M | $2.33M | $2.38M |
| Total assets | $3.11M | $3.16M | $3.25M | $3.15M | $3.76M | $3.87M | $3.75M | $3.78M |
| Current liabilities | $11.22M | $11.11M | $11.06M | $10.59M | $10.30M | $10.32M | $9.44M | $8.74M |
| Short-term debt | $132,822 | — | — | — | — | — | — | — |
| Long-term debt | $4.54M | $4.40M | $4.16M | $4.16M | $4.12M | $4.14M | $4.16M | $3.82M |
| Total debt | $4.68M | $4.40M | $4.16M | $4.16M | $4.12M | $4.14M | $4.16M | $3.82M |
| Total liabilities | $11.22M | $11.11M | $11.06M | $10.59M | $10.30M | $10.32M | $9.44M | $8.74M |
| Shareholders' equity | -$7.63M | -$7.47M | -$7.33M | -$6.96M | -$5.80M | -$5.71M | -$4.94M | -$4.48M |
| Net debt | $4.42M | $4.15M | $3.90M | $3.92M | $3.87M | $3.87M | $3.86M | $3.56M |
| Shares outstanding | 3.00B | 2.74B | 1.65B | 425.98M | 158.89M | 142.44M | 142.44M | 135.76M |
| Cash flow statement | ||||||||
| Operating cash flow | -$296,392 | -$54,844 | -$425,883 | $127,001 | $24,971 | $74,952 | -$710,507 | -$270,920 |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$296,392 | -$54,844 | -$425,883 | $127,001 | $24,971 | $74,952 | -$710,507 | -$270,920 |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $117,979 | $200,155 | -$22,839 | $69,424 | -$161,548 | $473,380 | $78,754 | $1.01M |
| Depreciation & amortization | $41,873 | $41,873 | $41,873 | $41,865 | $41,877 | $41,877 | $41,876 | $184,997 |
| Stock-based compensation | $110,665 | $109,463 | $108,260 | $110,666 | $110,666 | $109,462 | $108,260 | $209,060 |
Free plan shows the latest 8 periods; Pro shows all 61 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.